Elixiron Immunotherapeutics Inc.

Elixiron Immunotherapeutics employs advances in translational medicine to identify targets from clinical observations, and various drug modalities including biologics from phage display and single human B cell cloning platforms, to develop innovative therapies for cancer and immunological diseases. See our Pipeline of therapeutics under development below to learn more about our commitment to bring better, next-generation as well as new first-in-class immunotherapies to patients.

Pipeline

FOCUS AREA CANDIDATES

TARGET

Research

IND-enabling

Phase 1

Phase 2/3

IMMUNOLOGICAL AND DEGENERATIVE DISEASES

EI-001Vitiligo, HLH

IFN-g

antibodyPHASE 1

EI-1071Alzheimer's disease; Tenosynovial Giant Cell Tumors

CSF1R

small molecule inhibitorPHASE 1

CANCER

EI-012Multiple indication options

Undisclosed

antibodyRESEARCH

EI-011Multiple indication options

Undisclosed

bifunctionalRESEARCH

EI-003Multiple indication options

Undisclosed

bifunctionalRESEARCH

mobile key1.png mobile key2.png

Team

Management

Hung-Kai Kevin Chen

Chairman & Chief Executive Officer

Carrie Duan

Executive VP, Clinical Development

Huey-Wen Helen Hsiao

Vice President, Drug Discovery

James Hsu

Vice President, Finance & Operations

Pandelakis A. Koni

Executive Vice President, R&D

Scientific Advisory Board

Jean-Laurent Casanova, MD PhD

Rockefeller University

Ping-Chih Ho, PhD

University of Lausanne & Ludwig Institute

Li-Fan Lu, PhD

University of California San Diego

Francisco J. Quintana, PhD

Brigham and Women’s Hospital & Harvard University

News

Elixiron Immunotherapeutics Announces Orphan Drug Designation Granted to Interferon-Gamma-Neutralizing Antibody, EI 001 for the Treatment of Hemophagocytic Lymphohistiocytosis
September 6, 2022
Elixiron Immunotherapeutics Announces Orphan Drug Designation Granted to CSF-1R Inhibitor, EI-1071 for the Treatment of Idiopathic Pulmonary Fibrosis
August 2, 2022
Pathogenic autoantibodies to IFN-γ act through the impedance of receptor assembly and Fc-mediated response
July 20, 2022
Elixiron Immunotherapeutics Receives Grant from the Alzheimer’s Association to Trial Microglia-Targeting Immunotherapy
July 12, 2022
Elixiron dives into IFNγ and CSF-1R with pathway-centric approach
June 9, 2022
A bifunctional anti-PD-L1 antibody/IL-10 fusion protein targeting exhausted T cells for cancer immunotherapy
October 11, 2021
Elixiron Immunotherapeutics Closes $27 Million Series A-1 Financing Round to Progress Alzheimer’s Disease and Vitiligo Clinical-Stage Assets
August 23, 2021
Elixiron Immunotherapeutics Awarded Alzheimer’s Association Grant to Target Microglia in Alzheimer’s Disease
August 26, 2020
Taiwan Biotech and Elixiron Immunotherapeutics: Pharma Boardroom Interview
June 26, 2019
A potent and selective cFMS inhibitor EI-1071 inhibits CSF1R signaling and regulates tumor associated macrophages
September 14, 2018
Macrophage-secreted interleukin-35 regulates cancer cell plasticity to facilitate metastatic colonization
September 1, 2018

Contact

Investor inquiries: investors@elixiron.com

Media inquiries: media@elixiron.com

Careers and general inquiries: info@elixiron.com

Headquarters
No.1 South Building, 5th Floor, JinChuang Mansion,
4560 Jinke Rd, Shanghai 201210, China

Research Center
3 Park Street, 17th Floor, Taipei City 11503, Taiwan

Immunometabolism Discovery Laboratory
Route de la Corniche 6, 1066, Épalinges, Switzerland

Home
Pipeline
Team
News
Contact